Skip to main
PCSA
PCSA logo

Processa Pharmaceuticals (PCSA) Stock Forecast & Price Target

Processa Pharmaceuticals (PCSA) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Processa Pharmaceuticals Inc has shown improvement in its financial outlook, with the full-year 2026 net loss per share estimate narrowing to $0.15 from $0.20, suggesting effective management of expenses and shareholder dilution despite an increased outstanding share count. Positive interim data expected from the NGC-Cap mid-stage trial is anticipated to act as a significant value inflection point for the company, potentially enhancing investor confidence and stock performance. Furthermore, Processa's strategic investment initiatives and consideration of cryptocurrency treasury strategies indicate a proactive approach to financial growth and diversification, further contributing to a favorable market perspective.

Bears say

Processa Pharmaceuticals is projecting a full-year 2025 net loss of $0.43 per share, highlighting significant financial challenges ahead. The company faces multiple risks, including potential delays in regulatory approvals, increased competition leading to lower-than-expected pricing, and risks associated with partnerships that may hinder market penetration. Additionally, there are concerns regarding potential dilution risks in the near to medium term, which could further negatively impact investor sentiment and stock performance.

Processa Pharmaceuticals (PCSA) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Processa Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Processa Pharmaceuticals (PCSA) Forecast

Analysts have given Processa Pharmaceuticals (PCSA) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Processa Pharmaceuticals (PCSA) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Processa Pharmaceuticals (PCSA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.